Skip to main content
Erschienen in: Tumor Biology 5/2011

01.10.2011 | Research Article

Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary

verfasst von: Ja Seung Koo, Haeryoung Kim

Erschienen in: Tumor Biology | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Carcinoma of unknown primary (CUP) is a heterogeneous entity with different clinical and histological features. The aim of this study was to investigate the clinicopathological features and expression of proteins associated with carcinogenesis and tumor environment in different histological subtypes of CUP. Sixty-nine cases of CUP were subjected to immunohistochemistry for EGFR, phospho-EGFR, HER-2, phospho-HER-2, p53, ERCC1, RRM1, REDD1, HIF1α, COX-2, GLUT-1, 14-3-3σ, Phospho-mTOR, Phospho-S6, AMPKα1, Phospho-Akt, PDGF-β receptor, and caveolin-1, and fluorescence in situ hybridization for HER-2 gene amplification. Fourteen (20.3%) cases were poorly differentiated carcinoma, 24 (34.8%) were adenocarcinoma (AD), 17 (24.6%) were squamous cell carcinoma (SC), and 14 (20.3%) were undifferentiated carcinoma (UD). AD were mostly carcinomatosis type, while SC and UD were mostly nodal type (p < 0.001). SC showed more frequent EGFR overexpression (p < 0.001) and Glut-1 (p = 0.001). AD (p = 0.001) and carcinomatosis (p < 0.001) types showed shorter overall survival. SCs expressing Glut-1, HIF1α, and COX2 showed a poor prognosis (p = 0.048, 0.029, and 0.042, respectively). CUP shows various clinicopathological features according to the histological subtypes. SC is mainly associated with nodal metastasis in the head and neck, and frequent EGFR overexpression and Glut-1 expression. Glut-1, HIF1α, and COX2 expression in SC is associated with a poor prognosis.
Literatur
1.
Zurück zum Zitat Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005;54:243–50.PubMedCrossRef Pavlidis N, Fizazi K. Cancer of unknown primary (CUP). Crit Rev Oncol Hematol. 2005;54:243–50.PubMedCrossRef
2.
Zurück zum Zitat Haskell CM, Cochran AJ, Barsky SH, Steckel RJ. Metastasis of unknown origin. Curr Probl Cancer. 1988;12:5–58.PubMedCrossRef Haskell CM, Cochran AJ, Barsky SH, Steckel RJ. Metastasis of unknown origin. Curr Probl Cancer. 1988;12:5–58.PubMedCrossRef
3.
Zurück zum Zitat Krementz ET, Cerise EJ, Foster DS, Morgan Jr LR. Metastases of undetermined source. Curr Probl Cancer. 1979;4:4–37.PubMedCrossRef Krementz ET, Cerise EJ, Foster DS, Morgan Jr LR. Metastases of undetermined source. Curr Probl Cancer. 1979;4:4–37.PubMedCrossRef
4.
Zurück zum Zitat Lembersky BC, Thomas LC. Metastases of unknown primary site. Med Clin North Am. 1996;80:153–71.PubMedCrossRef Lembersky BC, Thomas LC. Metastases of unknown primary site. Med Clin North Am. 1996;80:153–71.PubMedCrossRef
5.
Zurück zum Zitat Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumours. Eur J Cancer. 2002;38:1810–2.PubMedCrossRef Levi F, Te VC, Erler G, Randimbison L, La Vecchia C. Epidemiology of unknown primary tumours. Eur J Cancer. 2002;38:1810–2.PubMedCrossRef
6.
Zurück zum Zitat van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in southeast netherlands, 1984–1992. Eur J Cancer. 2002;38:409–13.PubMedCrossRef van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in southeast netherlands, 1984–1992. Eur J Cancer. 2002;38:409–13.PubMedCrossRef
7.
Zurück zum Zitat van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: A literature review. Ann Oncol. 2003;14:191–6.PubMedCrossRef van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: A literature review. Ann Oncol. 2003;14:191–6.PubMedCrossRef
8.
Zurück zum Zitat Pentheroudakis G, Briasoulis E, Karavassilis V, Fountzilas G, Xeros N, Samelis G, et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective? Acta Oncol. 2005;44:155–60.PubMedCrossRef Pentheroudakis G, Briasoulis E, Karavassilis V, Fountzilas G, Xeros N, Samelis G, et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective? Acta Oncol. 2005;44:155–60.PubMedCrossRef
9.
Zurück zum Zitat Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.PubMedCrossRef Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.PubMedCrossRef
10.
Zurück zum Zitat Pentheroudakis G, Pavlidis N. Perspectives for targeted therapies in cancer of unknown primary site. Cancer Treat Rev. 2006;32:637–44.PubMedCrossRef Pentheroudakis G, Pavlidis N. Perspectives for targeted therapies in cancer of unknown primary site. Cancer Treat Rev. 2006;32:637–44.PubMedCrossRef
11.
Zurück zum Zitat Hainsworth JD, Lennington WJ, Greco FA. Overexpression of her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol. 2000;18:632–5.PubMed Hainsworth JD, Lennington WJ, Greco FA. Overexpression of her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol. 2000;18:632–5.PubMed
12.
Zurück zum Zitat Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N. Overexpression of c-myc, ras and c-erbb-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res. 1995;15:2563–7.PubMed Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N. Overexpression of c-myc, ras and c-erbb-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res. 1995;15:2563–7.PubMed
13.
Zurück zum Zitat Denko NC. Hypoxia, hif1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–13.PubMedCrossRef Denko NC. Hypoxia, hif1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–13.PubMedCrossRef
14.
Zurück zum Zitat Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer. 2008;8:56–61.PubMedCrossRef Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer. 2008;8:56–61.PubMedCrossRef
15.
Zurück zum Zitat Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. Energy metabolism in tumor cells. FEBS J. 2007;274:1393–418.PubMedCrossRef Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. Energy metabolism in tumor cells. FEBS J. 2007;274:1393–418.PubMedCrossRef
16.
Zurück zum Zitat Ortega AD, Sanchez-Arago M, Giner-Sanchez D, Sanchez-Cenizo L, Willers I, Cuezva JM. Glucose avidity of carcinomas. Cancer Lett. 2009;276:125–35.PubMedCrossRef Ortega AD, Sanchez-Arago M, Giner-Sanchez D, Sanchez-Cenizo L, Willers I, Cuezva JM. Glucose avidity of carcinomas. Cancer Lett. 2009;276:125–35.PubMedCrossRef
17.
Zurück zum Zitat Csiki I, Yanagisawa K, Haruki N, Nadaf S, Morrow JD, Johnson DH, et al. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res. 2006;66:143–50.PubMedCrossRef Csiki I, Yanagisawa K, Haruki N, Nadaf S, Morrow JD, Johnson DH, et al. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res. 2006;66:143–50.PubMedCrossRef
18.
Zurück zum Zitat Kaidi A, Qualtrough D, Williams AC, Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (hif)-1 promotes colorectal tumor cell survival and enhances hif-1 transcriptional activity during hypoxia. Cancer Res. 2006;66:6683–91.PubMedCrossRef Kaidi A, Qualtrough D, Williams AC, Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (hif)-1 promotes colorectal tumor cell survival and enhances hif-1 transcriptional activity during hypoxia. Cancer Res. 2006;66:6683–91.PubMedCrossRef
19.
Zurück zum Zitat Legan M, Luzar B, Marolt VF. Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. Scand J Gastroenterol. 2009;44:1101–8.PubMedCrossRef Legan M, Luzar B, Marolt VF. Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. Scand J Gastroenterol. 2009;44:1101–8.PubMedCrossRef
20.
Zurück zum Zitat Eckert AW, Lautner MH, Taubert H, Schubert J, Bilkenroth U. Expression of glut-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep. 2008;20:1381–5.PubMed Eckert AW, Lautner MH, Taubert H, Schubert J, Bilkenroth U. Expression of glut-1 is a prognostic marker for oral squamous cell carcinoma patients. Oncol Rep. 2008;20:1381–5.PubMed
21.
Zurück zum Zitat Choi YS, Kim SJ, Kim DS, Park SJ, Park Y, Shin HJ, et al. Glucose transporter-1 expression in squamous cell carcinoma of the tongue. Cancer Res Treat. 2007;39:109–15.PubMedCrossRef Choi YS, Kim SJ, Kim DS, Park SJ, Park Y, Shin HJ, et al. Glucose transporter-1 expression in squamous cell carcinoma of the tongue. Cancer Res Treat. 2007;39:109–15.PubMedCrossRef
22.
Zurück zum Zitat Pizzi S, Porzionato A, Pasquali C, Guidolin D, Sperti C, Fogar P, et al. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol. 2009;24:175–85.PubMed Pizzi S, Porzionato A, Pasquali C, Guidolin D, Sperti C, Fogar P, et al. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol. 2009;24:175–85.PubMed
23.
Zurück zum Zitat Endo M, Tateishi U, Seki K, Yamaguchi U, Nakatani F, Kawai A, et al. Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol. 2007;37:955–60.PubMedCrossRef Endo M, Tateishi U, Seki K, Yamaguchi U, Nakatani F, Kawai A, et al. Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol. 2007;37:955–60.PubMedCrossRef
24.
Zurück zum Zitat Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003;97:1573–81.PubMedCrossRef Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003;97:1573–81.PubMedCrossRef
25.
Zurück zum Zitat Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8:1831–7.PubMed Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8:1831–7.PubMed
26.
Zurück zum Zitat Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouyssegur J, et al. Hif-1alpha and ca ix staining in invasive breast carcinomas: Prognosis and treatment outcome. Int J Cancer. 2007;120:1451–8.PubMedCrossRef Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouyssegur J, et al. Hif-1alpha and ca ix staining in invasive breast carcinomas: Prognosis and treatment outcome. Int J Cancer. 2007;120:1451–8.PubMedCrossRef
27.
Zurück zum Zitat Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ. Prognostic significance of hypoxia-inducible factor-1alpha, twist1 and snail expression in resectable non-small cell lung cancer. Thorax. 2009;64:1082–9.PubMedCrossRef Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ. Prognostic significance of hypoxia-inducible factor-1alpha, twist1 and snail expression in resectable non-small cell lung cancer. Thorax. 2009;64:1082–9.PubMedCrossRef
28.
Zurück zum Zitat Chan CM, Ma BB, Hui EP, Wong SC, Mo FK, Leung SF, et al. Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma–a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor. Oral Oncol. 2007;43:373–8.PubMedCrossRef Chan CM, Ma BB, Hui EP, Wong SC, Mo FK, Leung SF, et al. Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma–a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor. Oral Oncol. 2007;43:373–8.PubMedCrossRef
29.
Zurück zum Zitat Ogane N, Yasuda M, Shimizu M, Miyazawa M, Kamoshida S, Ueda A, et al. Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol. 2010;14:23–9.PubMedCrossRef Ogane N, Yasuda M, Shimizu M, Miyazawa M, Kamoshida S, Ueda A, et al. Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol. 2010;14:23–9.PubMedCrossRef
30.
Zurück zum Zitat Xu CZ, Dong P, Li XY, Zhang ZJ. Expression and clinical significance of hypoxia-inducible factor-1alpha and cyclooxygenase-2 in laryngeal squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;44:57–62.PubMed Xu CZ, Dong P, Li XY, Zhang ZJ. Expression and clinical significance of hypoxia-inducible factor-1alpha and cyclooxygenase-2 in laryngeal squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009;44:57–62.PubMed
Metadaten
Titel
Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary
verfasst von
Ja Seung Koo
Haeryoung Kim
Publikationsdatum
01.10.2011
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2011
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-011-0190-5

Weitere Artikel der Ausgabe 5/2011

Tumor Biology 5/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.